A role for LYNX2 in anxiety-related behavior

Proceedings of the National Academy of Sciences of the United States of America

Volumn 106, Issue 11, 2009, Pages 4477-4482

  Tekinay, Ayse B ^a,d   Nong, Yi ^a   Miwa, Julie M ^a   Lieberam, Ivo ^b   Ibanez Tallon, Ines ^a,c   Greengard, Paul ^a   Heintz, Nathaniel ^a  

^a ROCKEFELLER UNIVERSITY   (United States)

^b Och Spine at New York Presbyterian Hospitals   (United States)

^c MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

^d BILKENT UNIVERSITY   (Turkey)

Author keywords

Anxiety; LYNX2; Nicotinic; Prefrontal cortex

Indexed keywords

GLUTAMIC ACID; LYNX2 PROTEIN; NICOTINE; NICOTINIC RECEPTOR; PROTEIN; UNCLASSIFIED DRUG;

AMYGDALOID NUCLEUS; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANXIETY DISORDER; ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; GENE; GENE DELETION; GENE EXPRESSION; GENE FUNCTION; GENE LOSS; HIPPOCAMPUS; HUMAN; HUMAN CELL; LYNX2 GENE; MOLECULAR MECHANICS; MOUSE; NEUROTRANSMISSION; NONHUMAN; PREFRONTAL CORTEX; PRIORITY JOURNAL; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; RECEPTOR BINDING; REGULATOR GENE; THALAMUS DORSOMEDIAL NUCLEUS;

ANIMALS; ANXIETY; ANXIETY DISORDERS; BEHAVIOR, ANIMAL; GLUTAMIC ACID; MEMBRANE GLYCOPROTEINS; MICE; MICE, MUTANT STRAINS; NEUROPEPTIDES; PROTEIN BINDING; RECEPTORS, NICOTINIC; SYNAPTIC TRANSMISSION;

MAMMALIA; MUS;

EID: 63149187256     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.0813109106     Document Type: Article

References (32)

1. Kessler RC, et al. (2005) Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 62:617-627.
2. Greenberg PE, et al. (1999) The economic burden of anxiety disorders in the 1990s. J Clin Psychiatry 60:427-435.
3. Phelps EA, LeDoux JE (2005) Contributions of the amygdala to emotion processing: From animal models to human behavior. Neuron 48:175-187.
4. Heisler LK, et al. (1998) Elevated anxiety and antidepressant-like responses in serotonin 5-HT1A receptor mutant mice. Proc Natl Acad Sci USA 95:15049-15054.
5. Kash SF, Tecott LH, Hodge C, Baekkeskov S (1999) Increased anxiety and altered responses to anxiolytics in mice deficient in the 65-kDa isoform of glutamic acid decarboxylase. Proc Natl Acad Sci USA 96:1698-1703.
6. Smith GW, et al. (1998) Corticotropin releasing factor receptor 1-deficient mice display decreased anxiety, impaired stress response, and aberrant neuroendocrine development. Neuron 20:1093-1102.
7. Rauch SL and Shin LM (2002) in Neuropsychopharmacology: The Fifth Generation of Progress, eds. Kenneth L Davis, D. C., Joseph T. Coyle, and Nemeroff, C. (American College of Neuropsychopharmacology), pp. 953-966.
8. Davis M (2002) in Neuropsychopharmacology: The Fifth Generation of Progress, eds. Davis KL, Coyle JT, Nemeroff C. (American College of Neuropsychopharmacology, Washington, DC), pp. 931-951.
9. Miwa JM, et al. (1999) lynx1, an Endogenous toxin-like modulator of nicotinic acetyl- choline receptors in the mammalian CNS. Neuron 23:105-114.
10. Ibanez-Tallon I, et al. (2002) Novel modulation of neuronal nicotinic acetylcholine receptors by association with the endogenous prototoxin lynx1. Neuron 33:893-903.
11. Chimienti F, et al. (2003) Identification of SLURP-1 as an epidermal neuromodulator explainsthe clinical phenotype of Mal de Meleda. Hum Mol Genet 12:3017-3024.
12. MiwaJM,et al. (2006)Theprototoxin lynx1 actson nicotinic acetylcholine receptorsto balance neuronal activity and survival in vivo. Neuron 51:587-600.
13. Neumeister A, Daher RJ and Charney DS (2005) Anxiety disorders: Noradrenergic neurotransmission. Handb Exp Pharmacol 205-223.
14. Picciotto MR, Brunzell DH, Caldarone BJ (2002)Effectofnicotine and nicotinicreceptorson anxietyand depression. Neuroreport 13:1097-1106.
15. LaksoM, et al. (1996) Efficient in vivo manipulation of mouse genomic sequences at the zygote stage. Proc Natl Acad Sci USA 93:5860-5865.
16. Irwin S(1968)Comprehensive observational assessment: Ia. Asystematic,quantitative procedure for assessing the behavioral and physiologic state of the mouse. Psychop- harmacologia 13:222-257.
17. Bourin M, Hascoet M (2003) The mouse light/dark box test. Eur J Pharmacol 463:55-65.
18. Nadler JJ, et al. (2004) Automated apparatus for quantitation of social approach behaviors in mice. Genes Brain Behav 3:303-314.
19. PellowS, File SE (1986) Anxiolytic and anxiogenicdrug effects on exploratoryactivity in an elevatedplus-maze: Anovel testofanxietyin therat. Pharmacol Biochem Behav 24:525-529.
20. Zorrilla EP, et al. (2002) Urocortin shares the memory modulating effects of corticotropin-releasing factor (CRF): Mediation byCRF1 receptors. Brain Res 952:200-210.
21. Salas R, et al. (2003) Altered anxiety-related responses in mutant mice lacking the beta 4 subunit of the nicotinic receptor. J Neurosci 23:6255-6263.
22. Booker TK, et al. (2007) Decreased anxiety-like behavior in beta3 nicotinic receptor subunit knockout mice. Pharmacol Biochem Behav 87:146-157.
23. Bamezai A (2004) Mouse Ly-6 proteins and their extended family: Markers of cell differentiation and regulators of cell signaling. Arch Immunol Ther Exp (Warsz) 52:255-266.
24. Swanson CJ, et al. (2005) Metabotropic glutamate receptors as novel targets for anxiety and stress disorders. Nat Rev Drug Discov 4:131-144.
25. Lambe EK, Picciotto MR, Aghajanian GK (2003) Nicotine induces glutamate release from thalamocortical terminals in prefrontal cortex. Neuropsychopharmacology 28:216-225.
26. Morissette SB, et al. (2007) Anxiety, anxiety disorders, tobacco use, and nicotine: A critical review of interrelationships. Psychol Bull 133:245-272.
27. Pomerleau OF (1986) Nicotine as a psychoactive drug: Anxiety and pain reduction. Psychopharmacol Bull 22:865-869.
28. Breslau N, Kilbey M, Andreski P (1991) Nicotine dependence, major depression, and anxietyin young adults. Arch Gen Psychiatry48:1069-1074.
29. Breslau N,Klein DF (1999)Smokingand panicattacks: An epidemiologic investigation. Arch Gen Psychiatry 56:1141-1147.
30. Labarca C, et al. (2001) Point mutant mice with hypersensitive alpha 4 nicotinic receptors show dopaminergic deficits and increased anxiety. Proc Natl Acad Sci USA 98:2786-2791.
31. Ross SA, et al. (2000) Phenotypic characterization of an alpha 4 neuronal nicotinic acetylcholine receptor subunit knock-out mouse. J Neurosci 20:6431-6441.
32. Gong S, et al. (2003) A gene expression atlas of the central nervous system based on bacterial artificial chromosomes. Nature 425:917-925.